PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28847910-5 2017 RESULTS: Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 7 +- 2 and 7 +- 2 mmHg, respectively (P < 0.05); and increased whole-body insulin-stimulated glucose uptake by 71% (3.4 +- 1.3 to 5.8 +- 2.1 mg/kg min; P < 0.01) in subjects with T2D. Pioglitazone 9-21 hemoglobin subunit alpha 1 Homo sapiens 30-34 29362626-4 2017 RESULTS: The mean change in HbA1c from baseline was -1.001 +- 0.83 with sitagliptin and -0.75 +- 1.20 with pioglitazone, and there were no significant difference between groups (P = 0.132). Pioglitazone 107-119 hemoglobin subunit alpha 1 Homo sapiens 28-32 27762511-16 2016 There was significant reduction in HbA1c with both pioglitazone and rosiglitazone but more with rosiglitazone. Pioglitazone 51-63 hemoglobin subunit alpha 1 Homo sapiens 35-39 28589542-5 2017 Drug-naive people with T2D do often show surprisingly strong reductions in HbA1c with metformin-based dual-agent oral treatment approaches; a recent report showed that even with baseline HbA1c >11%, the combination of metformin with a sulfonylurea, pioglitazone, or sitagliptin was associated with reduction in HbA1c from 11.6% to 6.0%. Pioglitazone 252-264 hemoglobin subunit alpha 1 Homo sapiens 75-79 20629618-7 2010 WHAT THE READER WILL GAIN: Initial therapy with a combination of sitagliptin (100 mg/day) and pioglitazone (30 mg/day) reduced HbA1c by > 2% starting from a baseline > 9%. Pioglitazone 94-106 hemoglobin subunit alpha 1 Homo sapiens 127-131 22067722-4 2012 Significant improvement in FPG and HbA1-c were shown by both rosiglitazone (p<0.003 and p<0.001, respectively) and pioglitazone (p<0.005 and p<0.001, respectively), compared with baseline, and pioglitazone showed greater beneficial effects on other parameters monitored, significantly reducing total cholesterol (TC) (p<=0.05). Pioglitazone 121-133 hemoglobin subunit alpha 1 Homo sapiens 35-39 22067722-4 2012 Significant improvement in FPG and HbA1-c were shown by both rosiglitazone (p<0.003 and p<0.001, respectively) and pioglitazone (p<0.005 and p<0.001, respectively), compared with baseline, and pioglitazone showed greater beneficial effects on other parameters monitored, significantly reducing total cholesterol (TC) (p<=0.05). Pioglitazone 205-217 hemoglobin subunit alpha 1 Homo sapiens 35-39 21492364-6 2011 RESULTS: Changes in HbA1c were -0.11% in the 0.5-mg group; -0.22% in the 1-mg group and -0.17% in the 1.5-mg rivoglitazone group; -0.06% in the 30-mg pioglitazone group and 0.61% in the placebo group. Pioglitazone 150-162 hemoglobin subunit alpha 1 Homo sapiens 20-24 23807528-3 2013 RESULTS: The mean changes in HbA1c from baseline was -0.94 +- 0.12% with pioglitazone and -0.71 +- 0.12% with sitagliptin, for a between-groups difference of -0.23 +- 0.16% (P = .16). Pioglitazone 73-85 hemoglobin subunit alpha 1 Homo sapiens 29-33 21682833-6 2011 RESULTS: The change from baseline in HbA1c after 12 weeks was significantly greater with alogliptin 12.5 mg added to pioglitazone and alogliptin 25 mg added to pioglitazone than with placebo added to pioglitazone (-0.91 and -0.97% vs. -0.19%; p < 0.0001). Pioglitazone 117-129 hemoglobin subunit alpha 1 Homo sapiens 37-41 21682833-6 2011 RESULTS: The change from baseline in HbA1c after 12 weeks was significantly greater with alogliptin 12.5 mg added to pioglitazone and alogliptin 25 mg added to pioglitazone than with placebo added to pioglitazone (-0.91 and -0.97% vs. -0.19%; p < 0.0001). Pioglitazone 160-172 hemoglobin subunit alpha 1 Homo sapiens 37-41 21682833-6 2011 RESULTS: The change from baseline in HbA1c after 12 weeks was significantly greater with alogliptin 12.5 mg added to pioglitazone and alogliptin 25 mg added to pioglitazone than with placebo added to pioglitazone (-0.91 and -0.97% vs. -0.19%; p < 0.0001). Pioglitazone 160-172 hemoglobin subunit alpha 1 Homo sapiens 37-41 21410628-8 2011 Patients taking linagliptin plus pioglitazone, compared with those receiving placebo plus pioglitazone, were more likely to achieve HbA1c of <7.0% (42.9 vs. 30.5%, respectively; p = 0.0051) and reduction in HbA1c of >=0.5% (75.0 vs. 50.8%, respectively; p < 0.0001). Pioglitazone 33-45 hemoglobin subunit alpha 1 Homo sapiens 132-136 21410628-8 2011 Patients taking linagliptin plus pioglitazone, compared with those receiving placebo plus pioglitazone, were more likely to achieve HbA1c of <7.0% (42.9 vs. 30.5%, respectively; p = 0.0051) and reduction in HbA1c of >=0.5% (75.0 vs. 50.8%, respectively; p < 0.0001). Pioglitazone 33-45 hemoglobin subunit alpha 1 Homo sapiens 210-214 20629618-8 2010 Adding sitagliptin (50 - 100 mg/day) to patients inadequately controlled on pioglitazone reduced HbA1c by 0.7 - 1.4% from a baseline of 8 - 8.5%. Pioglitazone 76-88 hemoglobin subunit alpha 1 Homo sapiens 97-101 19614948-1 2009 AIM: Published studies of patients treated with rosiglitazone or pioglitazone have reported greater reductions in HbA1c (A1C) than studies of patients treated with sitagliptin. Pioglitazone 65-77 hemoglobin subunit alpha 1 Homo sapiens 114-118 24692813-9 2008 The primary end point was change in HbA1c concentration after replacing metformin with pioglitazone. Pioglitazone 87-99 hemoglobin subunit alpha 1 Homo sapiens 36-40 18480556-6 2008 Treatment with acarbose and pioglitazone decreased HbA1c values by 0.49% and 0.63%, respectively. Pioglitazone 28-40 hemoglobin subunit alpha 1 Homo sapiens 51-55 16207627-4 2005 RESULTS: HbA1c improved in both treatment arms (pioglitazone: 7.52 +/- 0.85% to 6.71 +/- 0.89%, p < .0001; glimepiride: 7.44 +/- 0.89% to 6.83 +/- 0.85%, p < .0001). Pioglitazone 48-60 hemoglobin subunit alpha 1 Homo sapiens 9-13 16492206-10 2006 CONCLUSIONS: A comparable decrease in HbA1c and FBG was observed with pioglitazone and gliclazide. Pioglitazone 70-82 hemoglobin subunit alpha 1 Homo sapiens 38-42 19337535-5 2008 When started concomitantly in drug-naive patients, the combination of pioglitazone 30 mg and vildagliptin 100 mg qd reduces HbA1c by 1.9% after 24 weeks, compared with 1.1% with pioglitazone monotherapy. Pioglitazone 70-82 hemoglobin subunit alpha 1 Homo sapiens 124-128 17712875-12 2007 A mixed model analysis of variance on the 178 patients who started with combination therapy, either immediately or after a 3-6 month period on diet, showed that metformin plus gliclazide, repaglinide, or pioglitazone was associated with a gradual increase in HbA1c values. Pioglitazone 204-216 hemoglobin subunit alpha 1 Homo sapiens 259-263 15662596-10 2005 CONCLUSIONS: This pilot study indicates that at comparable fasting glucose concentration and at comparable HbA1c value pioglitazone is superior to sulfonylureas concerning the improvement of diabetic dyslipoproteinemia. Pioglitazone 119-131 hemoglobin subunit alpha 1 Homo sapiens 107-111 31376066-11 2019 Median HbA1c at index date was 7.8% and 8.8% in incident pioglitazone and insulin cohorts, and 7.5% and 7.6% in prevalent pioglitazone and insulin cohorts, respectively. Pioglitazone 57-69 hemoglobin subunit alpha 1 Homo sapiens 7-11 30926892-7 2019 Pioglitazone monotherapy showed equivalent efficacy as comparators in reducing HbA1c by 0.05% (95% CI: -0.21 to 0.11) and greater efficacy in reducing FBS level by 0.24 mmol/l (95% CI: -0.48 to -0.01). Pioglitazone 0-12 hemoglobin subunit alpha 1 Homo sapiens 79-83 11192132-16 2000 In the extension study, patients treated with open-label pioglitazone + metformin for 72 weeks had mean changes from baseline of -1.36% in HbA1c and -63.0 mg/dL in FPG. Pioglitazone 57-69 hemoglobin subunit alpha 1 Homo sapiens 139-143 10983737-5 2000 The addition of pioglitazone 30 mg/day to preexisting therapy with metformin, or of pioglitazone 15 or 30 mg/day to sulphonylurea, insulin or voglibose therapy, has been shown to decrease HbA1c and fasting blood glucose levels significantly in patients with poorly controlled type 2 diabetes mellitus. Pioglitazone 16-28 hemoglobin subunit alpha 1 Homo sapiens 188-192 10983737-5 2000 The addition of pioglitazone 30 mg/day to preexisting therapy with metformin, or of pioglitazone 15 or 30 mg/day to sulphonylurea, insulin or voglibose therapy, has been shown to decrease HbA1c and fasting blood glucose levels significantly in patients with poorly controlled type 2 diabetes mellitus. Pioglitazone 84-96 hemoglobin subunit alpha 1 Homo sapiens 188-192